The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

(Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers ...

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the ...